Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Philip Morris International Inc. ("Philip Morris" or the "Company") (NYSE: PM) investors concerning the Company and its officers' possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Philip Morris investigation page on our website

On December 20, 2017,  Reuters reported that former Phillip Morris employees and contractors "detailed irregularities in the clinical experiments that underpin Philip Morris International's application to the FDA for approval of its iQOS smoking device." The report further stated that Tamara Koval, who helped coordinate clinical trials for the device, was "excluded from meetings" after she "questioned the quality of some of the researchers and sites contracted to carry out those experiments."

On this news, shares of Philip Morris fell $3.75 or nearly 3.5% to close at $104.37 on December 20, 2017, thereby injuring investors.

Follow us for updates on Twitter:

If you purchased Philip Morris securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to, or visit our website at If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010